Neuropharmacological study of hetero[2,1]benzothiazepine derivatives analogues of tianeptine

Farmaco

Volumn 58, Issue 1, 2003, Pages 1-10

  Sánchez Mateo, Candelaria C ^a   Darias, Victoriano ^a   Expósito Orta, M Auxiliadora ^a   Albertos, Luz M ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Antidepressant activity; Heterobenzothiazepine derivatives; Neuroleptic activity; Neuropharmacology; Tianeptine analogues

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; APOMORPHINE; BENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; TIANEPTINE; THIAZEPINE DERIVATIVE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLIMBING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; EXPLORATORY BEHAVIOR; FEMALE; HEAD TWITCH; HYPOTHERMIA; INHIBITION KINETICS; MALE; MOUSE; MUSCLE RELAXATION; NEUROPHARMACOLOGY; NONHUMAN; STEREOTYPY; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; PHYSIOLOGY;

5-HYDROXYTRYPTOPHAN; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DRUG SYNERGISM; FEMALE; HYPOTHERMIA; MALE; MICE; THIAZEPINES;

EID: 0042467640     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(02)00021-6     Document Type: Article

References (26)

1. Judd L. Mood disorders in the general population represent an important and worldwide public health problem. Int. Clin. Psychopharmacol. 10:1995;5-10.
2. Holsboer F. Prospects for antidepressant drug discovery. Biol. Psychol. 57:2001;47-65.
3. Henry J.A. Toxicity of antidepressants: comparisons with fluoxetine. Int. Clin. Psychopharmacol. 6:1992;22-27.
4. Díaz J.A., Vega S., Expósito M.A., Sánchez-Mateo C.C., Darias V. Synthesis and antidepressant evaluation of new hetero[2,1]benzothiazepine derivatives. Arch. Pharm. Pharm. Med. Chem. 329:1996;352-360.
5. Mocaër E., Rettori M.C., Kamoun A. Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clin. Neuropharmacol. 11:1988;S32-S42.
6. Wilde M.I., Benfield P. Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 49:1995;411-439.
7. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24:1986;525-529.
8. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
9. Boissier J.R., Simon P. La reaction d'exploration chez la souris. Thérapie. 17:1962;1225-1232.
10. Tallarida R.J., Murray R.B. Manual of Pharmacologic Calculations with Computer Programs. second ed:1986;131-134 Springer, New York.
11. Bourin M. Le test permettant de prévoir chez l'animal l'activité antidépressive de la nouvelle molecule. Les Antidepresseurs. 1983;35-51 Ellipses, Paris.
12. Bourin M. Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests. Fundam. Clin. Pharmacol. 4:1990;49-64.
13. Puech A.J., Chermat R., Poncelet M., Doaré L., Simon P. Antagonism of hypothermia and behavioural response to apomorphine: a simple rapid and discriminating test for screening antidepressants and neuroleptics. Psychopharmacology. 75:1981;84-91.
14. Pawlowski L., Mazela H. Effects of antidepressant drugs, selective noradrenaline- or 5-hydroxytryptamine uptake inhibitors, on apomorphine-induced hypothermia in mice. Psychopharmacology. 88:1986;240-246.
15. Ortmann R., Waldmeir P.C., Radeke E., Felner A., Delini-Stula A. The effects of 5-HT uptake- and MAO inhibitors on L-5HTP-induced excitation in rats. Naunyn Shmiedebergs Arch. Pharmacol. 311:1980;185-192.
16. Burchall C.J., Soroko F.E., Rigdon G.C. Potentiation of the behavioural effects of 5-hydroxytryptophan by BW 1370U87, a selective monoamine oxidase-A inhibitor. Drug Dev. Res. 25:1992;209-213.
17. Puech A.J., Simon P., Boissier J.R. Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. Eur. J. Pharmacol. 50:1978;291-300.
18. Costentin J., Petit M., Dollfus S. Pharmacologie experiméntale des neuroleptiques et methods d'étude. Les Neuroleptiques: De la Neurobiologie des transmissions Dopaminergiques a la Thérapeutique. 1987;101-143 Ellipses, Paris.
19. Worms P. Behavioural pharmacology of the benzamides as compared to standard neuroleptics. Rotrosen J., Stanley M. The Benzamides: Pharmacology, Neurobiology and Clinical Aspects. 1982;7-16 Raven Press, New York.
20. Heffner T.G., Downs D.A., Meltzer L.T., Wiley J.N., Williams A.E. CI-943, a potential antipsychotic agent. I. Preclinical behavioural effects. J. Pharmacol. Exp. Ther. 251:1989;105-112.
21. Shank R.P., Gardocki J.F., Schneider C.R., Vaught J.L., Settler P.E., Maryanoff B.E., McComsey D.F. Preclinical evaluation of McN-5707 as a potential antidepressant. J. Pharmacol. Exp. Ther. 242:1987;74-84.
22. 1C receptors. Neurosci. Biobehav. Rev. 16:1992;95-105.
23. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 244:1988;685-693.
24. 2 receptor function: hypothesis for a faster antidepressant action. Pharmacol. Res. 30:1994;1-11.
25. Berendsen H.H.G. Interactions between 5-hydroxytryptamine receptor subtypes: Is a disturbed receptor balance contributing to the symptomatology of depression in humans. Pharmacol. Ther. 66:1995;17-37.
26. Lucki I. The spectrum of behaviours influenced by serotonin. Biol. Psychiatry. 44:1998;151-162.